Host-pathogen interactions are dynamic processes that encompass the techniques employed by pathogens to infect and overcome immune systems, as well as the ...

“Tolerogenic drugs re-establish tolerance to autoantigens ... by BHT-3021 to achieve long-term immune tolerance. These immune-modulating approaches could, in turn, be combined with ways of ...

However, considerable opportunities still exist to develop innate immune-modulating drugs, especially macrophage-targeted drugs, and this is where United Immunity could make its mark.

None of the immune-modulating drugs approved to treat ulcerative colitis – even biosimilars – are priced low enough to be cost-effective, says the Institute for Clinical and Economic Review ...

Argent BioPharma (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related ...

In the late 1960s, researchers at the Weizmann Institute of Science, including Professors Michael Sela and Ruth Arnon and Dr.

( MENAFN - EIN Presswire) market-grow.png" width="300" height="166" alt="Chronic Hepatitis B market Growth" /> David Correa Allied Market Research +1 800-792-5285 email us here Visit us on social ...

You will learn from expert researchers about immunological mechanisms that underpin IMIDs, and how our fundamental understanding of immunology, virology and microbiology has informed the design of ...

CM-24 is under clinical development by Purple Biotech and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate ...